Santen Pharmaceutical Co Ltd 2025 IR
The report outlines Santen's performance for the fiscal year ended March 31, 2025, and introduces its FY2025-2029 Medium-Term Management Plan. The company achieved its previous performance targets ahead of schedule, recording revenue of JPY 300.0 billion. Key highlights include the launch of Alesion eyelid cream in Japan and regulatory progress for Ryjusea to slow myopia progression. Santen also updated its Corporate Philosophy Framework and revised its materiality matrix to focus on product quality, stable supply, and environmental conservation.
Company: Santen Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 66
Santen Pharmaceutical Co Ltd
Santen Report
The report outlines Santen's performance for the fiscal year ended March 31, 2025, and introduces its FY2025-2029 Medium-Term Management Plan. The company achieved its previous performance targets ahead of schedule, recording revenue of JPY 300.0 billion. Key highlights include the launch of Alesion eyelid cream in Japan and regulatory progress for Ryjusea to slow myopia progression. Santen also updated its Corporate Philosophy Framework and revised its materiality matrix to focus on product quality, stable supply, and environmental conservation.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women in Management
Employees